X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

Lawyers for Michael Duxbury, a one-time regional sales manager for the blockbuster anemia drug Procrit, estimate that his False Claims Act case against the Johnson & Johnson Ortho Biotech Products subsidiary is worth at least $3 billion, and possibly as much as $10 billion. What they can’t understand, say Jan Schlichtmann (of “A Civil Action” fame) and Paul Simmerly of Heman Recor Araki Kaufman Simmerly & Jackson, is why the federal government seems to want no part of Duxbury’s allegations that Ortho Biotech induced medical centers to file false claims for Medicare reimbursement by providing free samples of Procrit.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]

 
 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.